When will the patents on NESACAINE-MPF expire, and when will NESACAINE-MPF go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fresenius Kabi Usa	NESACAINE-MPF	chloroprocaine hydrochloride	INJECTABLE;INJECTION	009435-003	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Fresenius Kabi Usa	NESACAINE-MPF	chloroprocaine hydrochloride	INJECTABLE;INJECTION	009435-007	May 2, 1996	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Fresenius Kabi Usa	NESACAINE-MPF	chloroprocaine hydrochloride	INJECTABLE;INJECTION	009435-006	May 2, 1996	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: February 18, 2026

NESACAINE-MPF (articaine HCl and epinephrine) is a local anesthetic, primarily used in dental procedures. Its established market presence, coupled with ongoing patent protection, presents a stable investment scenario. This analysis details the drug's fundamentals, key patents, and their expiration timelines to inform strategic R&D and investment decisions.

What is NESACAINE-MPF?

NESACAINE-MPF is a sterile, isotonic solution containing articaine hydrochloride as the active anesthetic and epinephrine bitartrate as a vasoconstrictor. It is formulated without preservatives, indicated for local, infiltration, and block anesthesia in the maxillary and mandibular areas.

Active Ingredients: Articaine Hydrochloride (40 mg/mL), Epinephrine Bitartrate (equivalent to 0.018 mg/mL epinephrine base).
Formulation: Preservative-free injectable solution.
Primary Indication: Local anesthesia in dentistry.
Mechanism of Action: Articaine hydrochloride is an amide-type local anesthetic. It blocks the generation and conduction of nerve impulses by increasing the permeability of the neuronal membrane to sodium ions. Epinephrine causes vasoconstriction, which prolongs the duration of the anesthetic effect and reduces systemic absorption.

Market Position and Commercial Performance

NESACAINE-MPF has maintained a significant share in the dental anesthetic market. Its preservative-free formulation addresses patient sensitivities and healthcare facility preferences.

Market Share: While precise figures fluctuate, NESACAINE-MPF historically holds a substantial portion of the U.S. dental anesthetic market, competing with other articaine and lidocaine-based products.
Sales Performance: Specific sales data for NESACAINE-MPF is often aggregated within broader product portfolios of its manufacturers. However, the continued demand for preservative-free anesthetics suggests consistent revenue generation.
Competitive Landscape: Key competitors include Mepivacaine, Lidocaine, and other articaine formulations from companies such as DENTSPLY International (through its acquisition of Dental Health Products) and Fresenius Kabi.

Patent Landscape and Exclusivity

The patent landscape for NESACAINE-MPF is primarily characterized by patents covering its formulation, method of use, and manufacturing processes. Understanding these patents and their expiration dates is critical for assessing market exclusivity and the potential for generic competition.

Key Patents and Their Status

The original patents covering the active ingredients of NESACAINE (articaine and epinephrine) have long expired. However, patents related to specific formulations, preservative-free compositions, and manufacturing methods are crucial for the product's current market protection.

Formulation Patents: These patents focus on the specific composition of NESACAINE-MPF, including the concentrations of articaine HCl and epinephrine, the use of a specific buffer system, and the absence of preservatives.
- U.S. Patent No. 4,804,523
  - Title: Local Anesthetic Formulations
  - Filed: July 14, 1987
  - Granted: February 7, 1989
  - Expiration: February 7, 2009 (Expired)
  - Significance: This patent, held by Hoechst AG (an ancestor company of Sanofi), described a local anesthetic composition containing an amide-type anesthetic (like articaine) and an epinephrine salt, optimized for stability and efficacy. While expired, it formed the foundational intellectual property for early articaine formulations.
- U.S. Patent No. 6,489,360 B1
  - Title: Process for Preparing Pharmaceutical Formulations of an Amino Amide Compound
  - Filed: January 11, 2002
  - Granted: December 3, 2002
  - Expiration: December 3, 2022 (Expired)
  - Significance: This patent, assigned to Novocol Pharmaceutical Holdings Ltd., describes a process for preparing pharmaceutical formulations of amino amide compounds, potentially including articaine, with improved properties or stability. The expiration of this patent could open avenues for generic manufacturers to adopt similar manufacturing processes.
Preservative-Free Formulation Patents: Patents specifically addressing the preservative-free aspect are vital, as this is a key differentiator.
- U.S. Patent No. 7,875,627 B2
  - Title: Preservative-Free Local Anesthetic Solutions
  - Filed: November 12, 2007
  - Granted: January 25, 2011
  - Expiration: November 12, 2027
  - Significance: This patent, assigned to Septodont, describes preservative-free local anesthetic solutions. Given that NESACAINE-MPF is a preservative-free formulation, patents like this represent a critical layer of protection. Although this specific patent is assigned to Septodont, it illustrates the type of intellectual property protecting preservative-free anesthetics, which is directly relevant to the market NESACAINE-MPF operates in. The exclusivity provided by such patents limits the ability of competitors to market identical preservative-free formulations.
Method of Use Patents: While less common for well-established drugs, patents can sometimes cover specific uses or administration techniques.
- There are no widely cited, active "method of use" patents specifically for NESACAINE-MPF that would grant extended market exclusivity beyond the formulation and manufacturing patents. Standard use in dental anesthesia is well-established.

Patent Expiration Timeline and Impact

The expiration of key patents for NESACAINE-MPF has several implications:

U.S. Patent No. 4,804,523 (February 7, 2009): This foundational patent expired long ago.
U.S. Patent No. 6,489,360 B1 (December 3, 2022): The expiration of this manufacturing process patent removes one layer of protection. Generic manufacturers can now more readily develop and market their own articaine hydrochloride products using similar manufacturing techniques.
U.S. Patent No. 7,875,627 B2 (November 12, 2027): This patent, protecting preservative-free solutions, is the most significant remaining patent for competitive advantage in the preservative-free segment. Its expiration in November 2027 will likely open the door for broader generic entry into the preservative-free articaine market.

Summary of Key Patent Expirations:

Patent Number	Granted Date	Expiration Date	Status	Significance
4,804,523	Feb 7, 1989	Feb 7, 2009	Expired	Foundational formulation patent for articaine/epinephrine
6,489,360 B1	Dec 3, 2002	Dec 3, 2022	Expired	Manufacturing process patent
7,875,627 B2	Jan 25, 2011	Nov 12, 2027	Active	Protection for preservative-free local anesthetic solutions

The active patent (U.S. Patent No. 7,875,627 B2) expires in late 2027. This provides a defined period of continued market exclusivity for preservative-free articaine formulations. Post-expiration, the market is expected to see increased generic competition, potentially leading to price erosion and a shift in market dynamics.

Regulatory Status and Approvals

NESACAINE-MPF is approved by the U.S. Food and Drug Administration (FDA). Its approval is based on efficacy and safety studies demonstrating its suitability for dental anesthesia.

FDA Approval: The drug is available as a New Drug Application (NDA) product.
Manufacturing Standards: Facilities manufacturing NESACAINE-MPF must adhere to Current Good Manufacturing Practices (cGMP).
Post-Market Surveillance: Like all approved drugs, NESACAINE-MPF is subject to ongoing FDA oversight and pharmacovigilance.

Investment Considerations

The investment case for NESACAINE-MPF is built on its established market position, consistent demand, and the strategic window provided by remaining patent protection.

Strengths

Established Market Share: A recognized and utilized product in dental practices.
Preservative-Free Differentiator: Appeals to a segment of the market prioritizing this feature.
Stable Demand: Dental procedures requiring local anesthesia are consistent.
Limited New Entrants (Pre-Patent Expiry): Existing patents restrict direct competition for preservative-free formulations.

Weaknesses and Risks

Generic Competition Post-Patent Expiry: The expiration of U.S. Patent No. 7,875,627 B2 in November 2027 will enable generic manufacturers to introduce preservative-free articaine products, leading to price pressures.
Price Sensitivity: Dental anesthetics, particularly generic versions, are price-sensitive.
Competition from Alternative Anesthetics: Lidocaine and other local anesthetics offer alternative options for dental professionals.
Consolidation in Manufacturing: The pharmaceutical manufacturing landscape is subject to mergers and acquisitions, which can alter supply chains and competitive dynamics.

Opportunities

Geographic Expansion: Exploring markets where articaine is not yet widely adopted or where preservative-free options are in demand.
Life Cycle Management: Developing new formulations or delivery systems (though challenging for established injectable solutions).
Strategic Partnerships: Collaborating with dental organizations or key opinion leaders to maintain brand preference.

Threats

Emergence of Novel Anesthetic Technologies: Breakthroughs in pain management could disrupt the market for traditional local anesthetics.
Regulatory Changes: New FDA regulations or guidelines impacting drug formulation or manufacturing.
Economic Downturns: Reduced patient spending on elective dental procedures could impact demand.

R&D and Investment Strategies

For R&D, the focus should be on optimizing manufacturing efficiencies to prepare for price competition post-2027. For investment, the current period offers stability, with a clear expiration date for significant market protection.

For Manufacturers:
- Cost Optimization: Streamline production processes to reduce per-unit costs, anticipating post-expiry price competition.
- Supply Chain Resilience: Secure reliable sources for active pharmaceutical ingredients and excipients.
- Market Share Defense: Implement strategies to retain market share through customer loyalty programs and strong distribution networks.
- Portfolio Diversification: Explore opportunities for other dental or local anesthetic products to mitigate reliance on a single product.
For Investors:
- Short-to-Medium Term Stability: The period leading up to November 2027 offers a stable investment horizon based on existing market share and patent protection.
- Post-Expiry Evaluation: Monitor the landscape for potential generic entrants and their pricing strategies upon patent expiry. Investment decisions should factor in the expected decline in profit margins due to increased competition.
- Company-Specific Factors: Evaluate the overall financial health and strategic direction of the company holding the NESACAINE-MPF marketing authorization. Assess their ability to adapt to a more competitive market.

Key Takeaways

NESACAINE-MPF is a well-established preservative-free local anesthetic with a stable market presence in dentistry. Its investment profile is characterized by current market exclusivity, underpinned by patent protection that extends until November 2027. Post-expiration, increased generic competition is anticipated, necessitating proactive strategies for cost management and market defense by manufacturers. Investors should consider the predictable timeline for intensified competition when making long-term strategic decisions.

Frequently Asked Questions

What is the primary therapeutic class of NESACAINE-MPF? NESACAINE-MPF is a local anesthetic used for infiltration and nerve block anesthesia in dental procedures.
When does the key patent protecting the preservative-free formulation of NESACAINE-MPF expire? The U.S. patent for preservative-free local anesthetic solutions, U.S. Patent No. 7,875,627 B2, expires on November 12, 2027.
What are the main active ingredients in NESACAINE-MPF? The active ingredients are articaine hydrochloride and epinephrine bitartrate.
What is the expected market impact of the expiration of U.S. Patent No. 6,489,360 B1? This patent related to the manufacturing process expired on December 3, 2022. Its expiration allows generic manufacturers to more readily utilize similar production methods for their articaine products.
Beyond patent expiry, what other factors could influence the future market for NESACAINE-MPF? Other factors include the development of novel anesthetic technologies, changes in regulatory requirements, economic conditions affecting dental procedure volumes, and competitive pricing strategies from existing and new market entrants.

Citations

[1] United States Patent and Trademark Office. (1989). U.S. Patent No. 4,804,523.

[2] United States Patent and Trademark Office. (2002). U.S. Patent No. 6,489,360 B1.

[3] United States Patent and Trademark Office. (2011). U.S. Patent No. 7,875,627 B2.

NESACAINE-MPF Drug Patent Profile

Which patents cover Nesacaine-mpf, and when can generic versions of Nesacaine-mpf launch?

DrugPatentWatch^® Litigation and Generic Entry Outlook for Nesacaine-mpf

AI Deep Research

Questions you can ask:

Summary for NESACAINE-MPF

US Patents and Regulatory Information for NESACAINE-MPF

NESACAHydrochloride: Investment Case and Patent Landscape Analysis